WebThese findings provide evidence for the benefit of urinary protein reduction in FSGS. Reductions in proteinuria warrant further evaluation as a potential surrogate for preservation of kidney function that may inform the design of future clinical trials. WebThe DUPLEX Study is a clinical research study looking at an investigational medication to see if it can help patients with primary focal segmental glomerulosclerosis (FSGS). We are looking for people with FSGS who may be interested in taking part in the study.
Did you know?
WebJan 8, 2024 · Introduction: Focal segmental glomerulosclerosis (FSGS), a histologic lesion in the kidney caused by varied pathophysiological processes, leads to end-stage kidney disease in a large proportion of patients. Sparsentan is a first-in-class orally active compound combining endothelin type A (ET A) receptor blockade with angiotensin II type … WebJun 23, 2024 · Goldfinch Bio’s TRACTION-2 clinical research trial is evaluating an investigational precision medicine, GFB-887, for the potential treatment of TRMCD and FSGS. The purpose of the trial is to determine if GFB-887 is safe and may help people who have high levels of protein in their urine due to kidney diseases caused by podocyte …
WebClinical Trials. The DUET and DUPLEX Studies. After completing the double-blind portion of the Phase 2 DUET Study, Travere Therapeutics initiated a global pivotal Phase 3 clinical trial in 2024 to support potential approval of sparsentan for patients with FSGS in the United States and Europe. WebMar 8, 2024 · Focal segmental glomerulosclerosis can be caused by a variety of conditions, such as diabetes, sickle cell disease, other kidney diseases and obesity. It can also be caused by an infection and drug …
WebFSGS may cause non-specific signs and symptoms, including protein in the urine, elevated levels of creatinine, and swelling. In many cases the cause of FSGS can not be determined. ... People participate in clinical trials for a variety of reasons. Participants with a disease may participate to help others, but also to possibly receive the ... WebMay 20, 2024 · An ongoing clinical trial is aimed at evaluating the efficacy, safety and pharmacokinetics of an oral APOL1 inhibitor, VX-147, in patients with an FSGS lesion …
WebFocal Segmental Glomerulosclerosis (FSGS) Focal Segmental Glomerulosclerosis (FSGS) is a type of kidney disease that involves scarring of the glomeruli. In FSGS, the scarring occurs in patches, or “foci,” and tends to affect only a portion of the glomeruli. ... At DaVita Clinical Research, we are committed to helping find new and innovative ...
WebMar 31, 2024 · Reiterova J, Safrankova H, Obeidova L, Stekrova J, Maixnerova D, Merta M, Tesar V. Mutational analysis of the NPHS2 gene in Czech patients with idiopathic nephrotic syndrome. Folia Biol (Praha). 2012;58(2):64-8. jedi fallen order second sister boss fightWebApr 3, 2024 · Results: This ongoing trial will report the efficacy, safety, pharmacokinetics, and biomarker results of PF-06730512 for patients with FSGS. Conclusion: Findings … own knowledge synonymsWebNov 23, 2024 · The FSGS Clinical Trial (FSGS-CT) was a multi-center, prospective, controlled, open label randomized trial designed to determine if treatment with mycophenolate mofetil (MMF) in conjunction with pulse steroids is superior to treatment with Cyclosporine-A (CSA) in inducing remission from proteinuria over 12 months. ... jedi fallen order raise the spireWebAug 16, 2024 · It is a global, randomized, multicenter, double-blind, parallel-arm, active-controlled clinical trial evaluating the safety and efficacy of 400mg of sparsentan, compared to 300mg of irbesartan, in 404 patients ages 18 years and up with IgAN and persistent proteinuria despite available ACE or ARB therapy. jedi fallen order return to zeffo walkthroughWebJun 6, 2024 · The study support ChemoCentryx’s plans to conduct a clinical endpoint study with CCR2 inhibitor CCX140 for FSGS, which has already been shown to have good safety and tolerability in hundreds of ... own knitted blank wearsWebJul 29, 2024 · We recently sat down with Dr. Ogo Egbuna, Vertex Pharmaceutical’s clinical development lead for their clinical trial in APOL1-mediated focal segmental glomerulosclerosis (FSGS) to learn a bit more about their program and why it’s exciting for the disease community. Dr. Egbuna is a board-certified nephrologist with a deep interest … own la giWeb10 rows · Jan 10, 2024 · A diagnosis of FSGS confirmed by kidney biopsy or documentation of a genetic mutation in a ... jedi fallen order secrets and chests